Literature DB >> 15852024

Lower incidence of Bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning.

S Yoshihara1, U Tateishi, T Ando, H Kunitoh, H Suyama, Y Onishi, R Tanosaki, S Mineishi.   

Abstract

Bronchiolitis obliterans (BO) is one of the most devastating complications after allogeneic stem cell transplantation (HSCT). However, its true pathogenesis is still to be elucidated. We conducted this study to find whether tissue damage due to high-dose chemo-radiotherapy is related to its pathogenesis. In all, 144 patients who received allogeneic HSCT between May 1999 and October 2001, and survived more than 80 days after transplant, were analyzed. Clinical course, pulmonary function tests, imaging studies including CT scan, and pathology results were reviewed. The overall incidence of BO was 9.7% (14/144). The cumulative incidence of BO at 2 years after transplant was 17% with myeloablative conditioning, and 2.3% with reduced intensity conditioning (P=0.024). Multivariate analysis showed that myeloablative conditioning was the only factor which affected the incidence of BO. Development of BO did not significantly affect the overall survival of patients. However, if they developed BO earlier than 200 days post transplant, the prognosis was significantly worse than if they developed it later than 200 days post transplant (P=0.003) or if they did not develop BO (P=0.002). Our results imply that tissue damage secondary to intensive chemo-radiotherapy may contribute to the pathogenesis of BO.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15852024     DOI: 10.1038/sj.bmt.1704985

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  15 in total

1.  Bronchiolitis obliterans with allogeneic hematopoietic cell transplantation: a 10-year experience of the Okayama BMT Group.

Authors:  Nobuharu Fujii; Koichi Nakase; Shoji Asakura; Keitaro Matsuo; Yuichiro Nawa; Kazutaka Sunami; Hisakazu Nishimori; Ken-Ichi Matsuoka; Eisei Kondo; Yoshinobu Maeda; Katsuji Shinagawa; Masamichi Hara; Mitsune Tanimoto
Journal:  Int J Hematol       Date:  2014-03-15       Impact factor: 2.490

2.  Bronchiolitis obliterans in patients undergoing allogeneic hematopoietic SCT.

Authors:  A G Vieira; V A M Funke; E C Nunes; R Frare; R Pasquini
Journal:  Bone Marrow Transplant       Date:  2014-03-10       Impact factor: 5.483

3.  Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation.

Authors:  Brandon K C Au; Margaret A Au; Jason W Chien
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-30       Impact factor: 5.742

4.  Evaluating the impact of antithymocyte globulin on lung function at 1 year after allogeneic stem cell transplantation.

Authors:  Filippo Milano; Margaret A Au; Michael J Boeckh; H Joachim Deeg; Jason W Chien
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-22       Impact factor: 5.742

5.  Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation.

Authors:  Chiaki Nakaseko; Shinichi Ozawa; Emiko Sakaida; Miwa Sakai; Yoshinobu Kanda; Kumi Oshima; Mineo Kurokawa; Satoshi Takahashi; Jun Ooi; Takayuki Shimizu; Akira Yokota; Fumiaki Yoshiba; Katsumichi Fujimaki; Heiwa Kanamori; Rika Sakai; Takayuki Saitoh; Tohru Sakura; Atsuo Maruta; Hisashi Sakamaki; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2011-03-19       Impact factor: 2.490

6.  Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients.

Authors:  Ajay Sheshadri; Roy F Chemaly; Amin M Alousi; Pankil K Shah; Gabriela Rondon; Lara Bashoura; Joumana Kmeid; Jacques Azzi; David W Blanco; Maryam Kaous; Burton F Dickey; Richard E Champlin; Dimpy P Shah
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-03       Impact factor: 5.742

Review 7.  Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease.

Authors:  Jason W Chien; Steven Duncan; Kirsten M Williams; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2009-11-05       Impact factor: 5.742

8.  Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT.

Authors:  S Dirou; F Malard; A Chambellan; P Chevallier; P Germaud; T Guillaume; J Delaunay; P Moreau; B Delasalle; P Lemarchand; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-02-17       Impact factor: 5.483

Review 9.  Challenges in pulmonary fibrosis. 2: Bronchiolocentric fibrosis.

Authors:  Jean-François Cordier
Journal:  Thorax       Date:  2007-07       Impact factor: 9.139

10.  Living-donor lobar lung transplantation for broncho-bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: does bronchiolitis obliterans recur in transplanted lungs?

Authors:  Hirokazu Okumura; Shigeki Ohtake; Yasuo Ontachi; Jun Ozaki; Shigeru Shimadoi; Yuko Waseda; Yukio Kondo; Hirohito Yamazaki; Akiyoshi Takami; Masahide Yasui; Hiroshi Date; Shinji Nakao
Journal:  Int J Hematol       Date:  2007-11       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.